Manal F. Abdelmalek, MD, MPH is Director of Hepatology and institutional lead for investigator-initiated and industry-sponsored multicenter clinical studies, Mayo Clinic, USA. Until recently, she was tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. Since first reporting NASH as a case of cryptogenic cirrhosis over 20 years ago, her research area of interest has focused on risk factors for NAFLD acquisition, fibrosis progression, and discovery of new and novel therapeutic interventions. She has expertise in the design and conduct of investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD. Her expertise includes transitioning new compounds to first-in-man early phase studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a standing member of NASH Clinical Research Network (NASH CRN) and principal investigator on several investigator-initiated and industry-sponsored studies for NAFLD/NASH. She has over 130 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD.
NASH treatment: State of the art in 2020
Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.Read More
Discovers new clinical trials and new biomarkersRead More
Prevalence of NAFLD (non-alcoholic fatty liver disease) affects approximately 25%…
So NAFLD (non-alcoholic fatty liver disease) is a spectrum of…